Wu D - Search Results

1

Tumor Vasculatures: A New Target for Cancer Immunotherapy.

Liu Z, Wang Y, Huang Y, Kim BYS, Shan H, Wu D, Jiang W. Liu Z, et al. Among authors: wu d. Trends Pharmacol Sci. 2019 Sep;40(9):613-623. doi: 10.1016/j.tips.2019.07.001. Epub 2019 Jul 20. Trends Pharmacol Sci. 2019. PMID: 31331639 Free PMC article. Review.

2

DLL1 orchestrates CD8⁺ T cells to induce long-term vascular normalization and tumor regression.

Zhang N, Yin R, Zhou P, Liu X, Fan P, Qian L, Dong L, Zhang C, Zheng X, Deng S, Kuai J, Liu Z, Jiang W, Wang X, Wu D, Huang Y. Zhang N, et al. Among authors: wu d. Proc Natl Acad Sci U S A. 2021 Jun 1;118(22):e2020057118. doi: 10.1073/pnas.2020057118. Proc Natl Acad Sci U S A. 2021. PMID: 34035167 Free PMC article.

3

[Biology and immunotherapy advance of interleukin 2 and interleukin 15-review].

Chen GH, Wu DP. Chen GH, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Aug;17(4):1088-92. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009. PMID: 19698267 Review. Chinese.

4

[Current research advance on cellular immunotherapy for leukemia-review].

Tian H, Chen GH, Xu Y, Qiao M, Liu HW, Wu DP. Tian H, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Oct;21(5):1326-30. doi: 10.7534/j.issn.1009-2137.2013.05.048. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013. PMID: 24156459 Review. Chinese.

5

Clinical Features of Chronic Graft-Versus-Host Disease Following Haploidentical Transplantation Combined with Infusion of a Cord Blood.

Tao T, Li Z, Chu XL, Zhu WJ, Xu Y, Wu DP, Ma X, Xue SL. Tao T, et al. Stem Cells Dev. 2019 Jun 1;28(11):745-753. doi: 10.1089/scd.2018.0259. Epub 2019 May 20. Stem Cells Dev. 2019. PMID: 30977441

6

A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients.

Yu ZP, Ding JH, Sun AN, Chen BA, Ge Z, Wu DP. Yu ZP, et al. Stem Cells Dev. 2019 Oct 15;28(20):1376-1383. doi: 10.1089/scd.2019.0139. Epub 2019 Sep 26. Stem Cells Dev. 2019. PMID: 31464164

7

[IAG regimen for patients with refractory/relapsed acute myeloid leukemia].

Yang Y, Ji CF, Zhang YM, Liu LM, He GS, Jin ZM, Ma X, Xue SL, He XF, Wu DP, Sun AN. Yang Y, et al. Zhonghua Xue Ye Xue Za Zhi. 2013 Jul;34(7):637-8. doi: 10.3760/cma.j.issn.0253-2727.2013.07.020. Zhonghua Xue Ye Xue Za Zhi. 2013. PMID: 23906465 Chinese. No abstract available.

8

Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.

Zhang J, Yang F, Qiu HY, Wu Q, Kong DQ, Zhou J, Han Y, Wu DP. Zhang J, et al. Leuk Lymphoma. 2019 Jun;60(6):1454-1461. doi: 10.1080/10428194.2018.1533127. Epub 2019 Feb 4. Leuk Lymphoma. 2019. PMID: 30714847

9

Case report: CD38-directed CAR-T cell therapy: A novel immunotherapy targeting CD38- positive blasts overcomes TKI and chemotherapy resistance of myeloid chronic myeloid leukemia in blastic phase.

Cui Q, Liang P, Dai H, Cui W, Cai M, Ding Z, Ma Q, Yin J, Li Z, Liu S, Kang L, Yao L, Cen J, Shen H, Zhu M, Yu L, Wu D, Tang X. Cui Q, et al. Among authors: wu d. Front Immunol. 2022 Nov 29;13:1012981. doi: 10.3389/fimmu.2022.1012981. eCollection 2022. Front Immunol. 2022. PMID: 36524116 Free PMC article.

10

[Actions of keratinocyte growth factor in leukemic mice allogeneic umbilical cord blood cell transplantation].

Chen GH, Wang Y, Qiao SM, Feng YF, Zhu ZL, Wu DP. Chen GH, et al. Zhonghua Yi Xue Za Zhi. 2011 Nov 1;91(40):2863-7. Zhonghua Yi Xue Za Zhi. 2011. PMID: 22333552 Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

23,460 results

Search Page